In the context of melanoma, prevalent mutations in BRAF, NRAS, MEK, and KIT oncogenes have already made possible the development of specific targeted therapies directed at the MAPK/ERK pathway, often constitutionally activated in melanoma [59]. Here, NRAS is linked to melanoma.